Nigerian medical journal : journal of the Nigeria Medical Association · 2025
Clinical Challenges with Neovascular Glaucoma-Patient Tailored Strategies and Outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rao Aparna, Padhi Tapas Ranjan, M Sanjib Khan
Аннотация
BACKGROUND: To report the outcomes of patient-tailored concurrent combined surgery for retinal ischemia and intraocular pressure (IOP) control in neovascular glaucoma (NVG) with or without cataract. Methodology: Ninety-seven (97) eyes with NVG seen between January 2022-September 2023 at a tertiary eye care centre, 6 eyes (4 proliferative diabetic retinopathy and 2 retinal vein occlusion) that underwent concurrent retinal and glaucoma procedures with or without cataract surgery, were recruited. Outcomes after surgery were based on the World Glaucoma Association guidelines on the reporting of glaucoma surgical trials that comprise functional and surgical parameters.
RESULTS: The IOP reduced by>50% from baseline in all 6 eyes, with one eye developing shallow AC by overstraining and 3 eyes developing transient self-resolving hyphema. Two eyes received additional bevacizumab (n=1) or ranibizumab (n=1) injections for persistent DME at 4 and 5 months after surgery. The final IOP was reduced in all eyes at the final follow-up of 6±1.2 months, with one eye requiring 2 medications for IOP control.
CONCLUSION: The outcomes after concurrent retinal and glaucoma filtering surgery in NVG may provide favourable outcomes comparable to the traditional stepwise approach to management provided these are offered on a case-case basis.
RESULTS: The IOP reduced by>50% from baseline in all 6 eyes, with one eye developing shallow AC by overstraining and 3 eyes developing transient self-resolving hyphema. Two eyes received additional bevacizumab (n=1) or ranibizumab (n=1) injections for persistent DME at 4 and 5 months after surgery. The final IOP was reduced in all eyes at the final follow-up of 6±1.2 months, with one eye requiring 2 medications for IOP control.
CONCLUSION: The outcomes after concurrent retinal and glaucoma filtering surgery in NVG may provide favourable outcomes comparable to the traditional stepwise approach to management provided these are offered on a case-case basis.